Inhibitors of acyl-CoA:cholesterol O-acyltransferase.: 2.: Identification and structure-activity relationships of a novel series of N-alkyl-N-(heteroaryl-substituted benzyl)-N′-arylureas

被引:72
作者
Tanaka, A
Terasawa, T
Hagihara, H
Sakuma, Y
Ishibe, N
Sawada, M
Takasugi, H
Tanaka, H
机构
[1] Fujisawa Pharmaceut Co Ltd, Med Chem Res Labs, Yodogawa Ku, Osaka 532, Japan
[2] Fujisawa Pharmaceut Co Ltd, Med Biol Res Labs, Yodogawa Ku, Osaka 532, Japan
[3] Fujisawa Pharmaceut Co Ltd, New Drug Res Labs, Yodogawa Ku, Osaka 532, Japan
[4] Fujisawa Pharmaceut Co Ltd, Exploratory Res Labs, Tsukuba, Ibaraki 30026, Japan
关键词
D O I
10.1021/jm9800853
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of N-alkyl-N-(heteroaryl-substituted benzyl)-N'-arylurea and related derivatives represented by 2 and 3 have been prepared and evaluated for their ability to inhibit acyl-CoA: cholesterol O-acyltransferase in vitro and to lower plasma cholesterol levels in cholesterol-fed rats in vivo. Among these novel compounds, the type 3 series was superior. A pyrazol-3-yl group on the N-benzyl group of this trisubstituted urea (i.e. 3, Ar-1 = pyrazol-3-yl) was identified as a heteroaromatic ring providing a good profile of biological activity. As a result of optimization of the combination with the N-alkyl group (R) and N-aryl group (Ar-3), compound 3aq (FR186054) was identified as a new, orally efficacious ACAT inhibitor, which exhibited potent in vitro ACAT inhibitory activity (rabbit intestinal microsomes IC50 = 99 nM) and excellent hypocholesterolemic effects in cholesterol-fed rats, irrespective of administration mode (ED50 = 0.046 mg/kg dosed via the diet, ED50 = 0.44 mg/kg administered by gavage in PEG400 vehicle). Moreover, a toxicological study revealed compound 3aq to be nontoxic to the adrenal glands of dogs when tested at a single dose of 10 mg/kg po.
引用
收藏
页码:2390 / 2410
页数:21
相关论文
共 56 条
[21]   POLYARYLENES AND POLY(ARYLENEVINYLENE)S .5. SYNTHESIS OF TETRAALKYL-SUBSTITUTED OLIGO(1,4-NAPHTHYLENE)S AND CYCLIZATION TO SOLUBLE OLIGO(PERI-NAPHTHYLENE)S [J].
KOCH, KH ;
MULLEN, K .
CHEMISCHE BERICHTE, 1991, 124 (09) :2091-2100
[22]  
KRAUSE BR, 1993, J LIPID RES, V34, P279
[23]  
LARGIS EE, 1989, J LIPID RES, V30, P681
[24]  
LARGIS EE, 1989, 10TH INT S DRUGS AFF, P33
[25]  
LEE HT, 1995, EXPERT OPIN THER PAT, V5, P397
[26]  
MARTIN MJ, 1986, LANCET, V2, P933
[27]   ACAT INHIBITORS AS ANTIATHEROSCLEROTIC AGENTS - COMPOUNDS AND MECHANISMS [J].
MATSUDA, K .
MEDICINAL RESEARCH REVIEWS, 1994, 14 (03) :271-305
[28]   Difference between normal and WHHL rabbits in susceptibility to the adrenal toxicity of an acyl-CoA:cholesterol acyltransferase inhibitor, FR145237 [J].
Matsuo, M ;
Hashimoto, M ;
Suzuki, J ;
Iwanami, K ;
Tomoi, M ;
Shimomura, K .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1996, 140 (02) :387-392
[29]   NEW APPROACHES TO ATHEROSCLEROSIS - AN OVERVIEW [J].
MCCARTHY, PA .
MEDICINAL RESEARCH REVIEWS, 1993, 13 (02) :139-159
[30]   Inhibitors of acyl-CoA:cholesterol O-acyltransferase. Synthesis and pharmacological activity of (+/-)-2-dodecyl-alpha-phenyl-N-(2,4,6-trimethoxyphenyl)-2H-tetrazole-5-acetamide and structurally related tetrazole amide derivatives [J].
OBrien, PM ;
Sliskovic, DR ;
Picard, JA ;
Lee, HT ;
Purchase, CF ;
Roth, BD ;
White, AD ;
Anderson, M ;
Mueller, SB ;
Bocan, T ;
Bousley, R ;
Hamelehle, KL ;
Homan, R ;
Lee, P ;
Krause, BR ;
Reindel, JF ;
Stanfield, RL ;
Turluck, D .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (12) :2354-2366